Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.67 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.60 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.60 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.57 |
| ▸ | CA12 | O43570 | 1/20 | 0.54 |
| ▸ | CA1 | P00915 | 1/20 | 0.54 |
| ▸ | CA2 | P00918 | 1/20 | 0.54 |
| ▸ | CA9 | Q16790 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | PTPRB | P23467 | 1/20 | 0.48 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.48 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | LOX | P28300 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3932525 | 0.87 | LOXL2 (0.66) | LOXL2CYP4F2CYP4A11SLC7A5CA12 | |
| SCHEMBL35360 | 0.86 | LOXL2 (0.64) | LOXL2CYP4F2CYP4A11SLC7A5CA12 | |
| SCHEMBL1272718 | 0.84 | LOXL2 (0.62) | LOXL2CYP4F2CYP4A11SLC7A5CA12 | |
| SCHEMBL5969642 | 0.84 | LOXL2 (0.62) | LOXL2CYP4F2CYP4A11SLC7A5CA12 | |
| SCHEMBL25630182 | 0.82 | CA2 (0.50) | LOXL2CA12CA1CA2CA9 | |
| SCHEMBL3929990 | 0.82 | LOXL2 (0.59) | LOXL2CYP4F2CYP4A11SLC7A5POLB | |
| SCHEMBL5041329 | 0.80 | CA1 (0.52) | CA1CA2CA9POLBMAPT | |
| SCHEMBL22193540 | 0.80 | LOXL2 (0.62) | LOXL2CYP4F2CYP4A11CA12CA1 | |
| SCHEMBL31720548 | 0.80 | FOLH1 (0.58) | CA1CA2CA9HIF1AFOLH1 | |
| SCHEMBL307892 | 0.80 | LOXL2 (1.00) | LOXL2CYP4F2CYP4A11SLC7A5MRGPRX4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220227707-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2022-07-21 | — | — | US | disclosed |
| EP-3914583-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | Novartis AG (CH) | 2021-12-01 | — | — | EP | disclosed |
| CN-113316566-A | Compounds and compositions for treating conditions associated with NLRP activity | 诺华股份有限公司 | 2021-08-27 | — | — | CN | disclosed |
| WO-2020154321-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS INFLAMMASOME RESEARCH, INC. (US) | 2020-07-30 | — | — | WO | disclosed |
| WO-2020154321-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS INFLAMMASOME RESEARCH, INC. (US) | 2020-07-30 | — | — | WO | disclosed |
| EP-2528895-B1 | TRYPSIN-LIKE SERINE PROTEASE INHIBITORS, AND THEIR PREPARATION AND USE | MEDICINES CO LEIPZIG GMBH (DE) | 2016-03-30 | — | — | EP | disclosed |
| WO-2011094496-A2 | TRYPSIN-LIKE SERINE PROTEASE INHIBITORS, AND THEIR PREPARATION AND USE | THE MEDICINES COMPANY (US) | 2011-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220227707-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NLRP1, NLRP3, NOD1 | LOXL2 1003/4885CYP4F2 1028/4885CYP4A11 276/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.